JP2017517550A - トレプロスチニル製剤 - Google Patents
トレプロスチニル製剤 Download PDFInfo
- Publication number
- JP2017517550A JP2017517550A JP2016572651A JP2016572651A JP2017517550A JP 2017517550 A JP2017517550 A JP 2017517550A JP 2016572651 A JP2016572651 A JP 2016572651A JP 2016572651 A JP2016572651 A JP 2016572651A JP 2017517550 A JP2017517550 A JP 2017517550A
- Authority
- JP
- Japan
- Prior art keywords
- treprostinil
- ion exchange
- exchange resin
- formulation
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本出願は、2014年6月13日に出願された米国仮出願第62/011,689号の優先権を主張し、その全体が参照により本明細書に組み込まれる。
本開示はプロスタサイクリン誘導体、例えばトレプロスチニルとのイオン交換樹脂複合体に関する。
一実施形態は、a)トレプロスチニル又はその誘導体、及びb)アニオンイオン交換樹脂、を含有する組成物であり、それは好ましくはイオン複合体の形態である。
特に明記しない限り、「a」又は「an」は1又は複数を意味する。
導入
薬物(トレプロスチニル)の放出速度が制御され得るトレプロスチニルの徐放性液体剤形を開発するために研究が行われた。本研究において、トレプロスチニルとイオン交換樹脂(IER)、すなわちコレスチラミン樹脂との複合体はトレプロスチニルの徐放性剤形における使用のための候補とみなされた。
トレプロスチニルジオールアミン(UT−15C)及びトレプロスチニル(UT−15)の化学式は以下の通りである。
UV吸収測定を、220nmから350nmのFluostar Omega BMG Labtech UV分光光度計を用いておおよそ0.1mg/mLのトレプロスチニルジオールアミン溶液で行って、λmaxを決定した。2つの標準曲線を228nm及び270nmで既知濃度のトレプロスチニルを用いて確定した。IERへの結合及び非結合トレプロスチニル間の平衡を達成する時間を決定した。1グラムの樹脂を10mg/mLのトレプロスチニル溶液の100mLに添加した。懸濁液を4時間撹拌し、1mLの試料を30、60、90、120、180、及び240分で採取した。各試料を0.45μmのPTFEフィルターで濾過し、得られた溶液をトレプロスチニル濃度についてUV分光光度法によって分析した。既知濃度のトレプロスチニル及び1グラムの樹脂を用いて、1:0.5、1:1、1:2、及び1:4の、樹脂:トレプロスチニル(w/w)の比で、複合体形成実験を行った。2つの樹脂、PUROLITE(商標)及びDUOLITE(商標)、を別々に評価した。樹脂のグラム当たりの複合体化したトレプロスチニルの量を初期と最終トレプロスチニル濃度との差に基づいて計算した。パーセントの充填効率を、以下の方程式:(1-[非結合トレプロスチニル]/[初期トレプロスチニル])*100、に基づいて計算した。Leica DM IL LED光学顕微鏡及びLeica DMC2900顕微鏡カメラを使用して、トレプロスチニルとの複合体形成前後の各樹脂について写真を撮影した。
図1〜6は実験の結果を示す。特に、図1は、228nm及び270nmで最大値を有するトレプロスチニルジエタノールアミンのUV吸収スペクトルを示す。図2A及び2Bは、228nm(2A)及び270nm(2B)でのトレプロスチニル吸収に基づく非結合トレプロスチニル(ジエタノールアミン)の濃度を決定するための検量線を示す。270nmでの曲線を複合体形成実験における全ての濃度を計算するために使用した。
トレプロスチニルは228nm及び270nmの波長でλmaxを有する。トレプロスチニルはコレスチラミン樹脂とイオン性複合体を形成する。1時間の撹拌後、当該樹脂への結合及び非結合トレプロスチニル間の平衡を達成した。トレプロスチニルジエタノールアミンの濃度が上がるにつれて、より多くの薬物が樹脂に複合体化したが、結合したトレプロスチニルの最大量が1.6g/g樹脂に達すると定常に達し始めた。より低いトレプロスチニルジエタノールアミンの濃度では、ほぼ全ての薬物が樹脂に結合した場合に充填はより高効率であった。複合体形成のための好ましい比率は、最も少ない廃棄量で最も多くの薬物が結合することができる、樹脂:薬物が1:1で有り得る。
Pande S.V.ら、International Journal of Advances in Pharmaceutical Sciences 2.2.1(2011):8-16. Print、その全体が参照により組み込まれる。
Claims (20)
- a)トレプロスチニル又はその誘導体、及びb)アニオンイオン交換樹脂、を含有する組成物。
- 前記トレプロスチニル又はその誘導体が前記アニオン交換樹脂とイオン複合体を形成する、請求項1に記載の組成物。
- トレプロスチニルが遊離酸である、請求項1に記載の組成物。
- トレプロスチニルが、トレプロスチニルの薬学的に許容される塩である、請求項1に記載の組成物。
- 前記イオン交換樹脂が胆汁酸封鎖剤(bile acid sequestrant)を含む、請求項1に記載の組成物。
- 前記胆汁酸封鎖剤がコレスチラミン、コロセべラム(colosevelam)、及びコレスチポールからなる群から選択される、請求項5に記載の組成物。
- 前記イオン交換樹脂がコレスチラミン樹脂である、請求項6に記載の組成物。
- トレプロスチニルとコレスチラミン樹脂との重量対重量比が1:2から2:1である、請求項7に記載の組成物。
- トレプロスチニル及びコレスチラミン樹脂の水性分散液を用いて調製され、ここで、当該分散液が0.1mg/mlから100mg/mlのトレプロスチニルの濃度を有する、請求項7に記載の組成物。
- i)トレプロスチニル又はその誘導体とアニオンイオン交換樹脂との間で形成されたイオン複合体、及びii)薬学的に許容される担体、を含む医薬製剤。
- 懸濁液である、請求項10に記載の製剤。
- 錠剤及びカプセル剤から選択される固体剤形である、請求項10に記載の製剤。
- 経口送達のための液体剤形である、請求項10に記載の製剤。
- イオン複合体上に水不溶性膜コーティングをさらに含む、請求項10に記載の製剤。
- 前記コーティングがポリマーを含む、請求項14に記載の製剤。
- 前記コーティングが酢酸セルロースを含む、請求項14に記載の製剤。
- 前記イオン複合体からの前記トレプロスチニルの放出を延長し又は変更するように構成された放出遅延剤(release retardant)をさらに含む、請求項10に記載の製剤。
- 1時間から36時間までの期間にわたってトレプロスチニルの放出制御を提供する放出制御製剤である、請求項10に記載の製剤。
- 請求項10に記載の製剤の治療上有効量を、肺高血圧症の治療を必要とする対象に投与することを含む、当該肺高血圧症の治療方法。
- トレプロスチニル製剤の調製方法であって、以下、
イオン交換樹脂と、トレプロスチニル又はその誘導体を含む溶液とを混合して、イオン交換樹脂とトレプロスチニル又はその誘導体とのイオン複合体を含む懸濁液を形成すること、
を含む、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462011689P | 2014-06-13 | 2014-06-13 | |
US62/011,689 | 2014-06-13 | ||
PCT/US2015/035595 WO2015192030A1 (en) | 2014-06-13 | 2015-06-12 | Treprostinil formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2017517550A true JP2017517550A (ja) | 2017-06-29 |
Family
ID=53487449
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016572651A Pending JP2017517550A (ja) | 2014-06-13 | 2015-06-12 | トレプロスチニル製剤 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20170095432A1 (ja) |
EP (1) | EP3164155B1 (ja) |
JP (1) | JP2017517550A (ja) |
KR (1) | KR102512890B1 (ja) |
CN (1) | CN106573066A (ja) |
AU (1) | AU2015274377B2 (ja) |
CA (1) | CA2952223C (ja) |
ES (1) | ES2908142T3 (ja) |
WO (1) | WO2015192030A1 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108947843A (zh) | 2013-10-25 | 2018-12-07 | 英斯梅德股份有限公司 | 前列环素化合物、其组合物及使用方法 |
CA2967385C (en) | 2014-11-18 | 2023-05-16 | Insmed Incorporated | Methods of manufacturing treprostinil and treprostinil derivative prodrugs |
PL3328361T3 (pl) | 2015-07-27 | 2021-12-13 | Sun Pharma Advanced Research Company Ltd | Cząstki nanożywicy zawierające lek |
JP6786240B2 (ja) * | 2016-03-31 | 2020-11-18 | 小林製薬株式会社 | 粘性経口組成物 |
US11458098B2 (en) | 2019-04-29 | 2022-10-04 | Insmed Incorporated | Dry powder compositions of treprostinil prodrugs and methods of use thereof |
US20210022994A1 (en) * | 2019-07-22 | 2021-01-28 | Lupin Holdings, B.V. | Sustained release trepostinil-compound microparticle compositions |
US11634443B2 (en) | 2019-08-23 | 2023-04-25 | United Therapeutics Corporation | Treprostinil prodrugs |
EP4135707A1 (en) | 2020-04-17 | 2023-02-22 | United Therapeutics Corporation | Treprostinil for use in the treatment of intersitial lung disease |
IL298591A (en) | 2020-06-09 | 2023-01-01 | United Therapeutics Corp | Pomeryl dictopiperidine prodrugs of treprostinil |
IL303668A (en) | 2020-12-14 | 2023-08-01 | United Therapeutics Corp | Stable treprostinil prodrugs and their uses for the treatment of diseases |
CN112704740B (zh) * | 2020-12-31 | 2021-10-29 | 国药集团致君(深圳)坪山制药有限公司 | 孟鲁司特树脂复合物及其制备方法和应用 |
WO2023147443A2 (en) * | 2022-01-26 | 2023-08-03 | Tulex Pharmaceuticals Inc. | Novel compositions |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009530298A (ja) * | 2006-03-16 | 2009-08-27 | トリス・フアルマ・インコーポレーテツド | 薬剤−イオン交換樹脂複合体を含有する放出調節製剤 |
WO2009158010A1 (en) * | 2008-06-27 | 2009-12-30 | Concert Pharmaceuticals, Inc. | Prostacyclin analogs |
JP2011500567A (ja) * | 2007-10-11 | 2011-01-06 | フィリップ・モーリス・プロダクツ・ソシエテ・アノニム | 生理活性物質送達のための押出可能な組成物及び押出組成物、その製造方法並びにその使用方法 |
JP2011519927A (ja) * | 2008-05-08 | 2011-07-14 | ユナイテッド セラピューティクス コーポレーション | トレプロスチニル一水和物 |
WO2013024052A1 (en) * | 2011-08-12 | 2013-02-21 | Ascendis Pharma A/S | Carrier-linked treprostinil prodrugs |
WO2013024051A1 (en) * | 2011-08-12 | 2013-02-21 | Ascendis Pharma A/S | Sustained release composition of prostacyclin |
JP2014510128A (ja) * | 2011-04-06 | 2014-04-24 | リリアナ・ソヴィッチ・ブルキチッチ | 医薬組成物 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4093657A (en) | 1976-04-09 | 1978-06-06 | Merck & Co., Inc. | Process for preparing monomer of bile acid sequestrant polymer |
US4185088A (en) | 1977-02-17 | 1980-01-22 | Merck & Co., Inc. | Non-adhesive ionene quaternary polymer compositions useful as bile acid sequestrants |
US4306075A (en) | 1980-03-28 | 1981-12-15 | The Upjohn Company | Composition and process |
US4593073A (en) | 1985-04-23 | 1986-06-03 | The Royal Institution For The Advancement Of Learing (Mcgill Univ.) | Polymer resins with amino acid containing pendants for sorption of bile pigments and bile acids |
GB8814438D0 (en) | 1988-06-17 | 1988-07-20 | Wellcome Found | Compounds for use in medicine |
US5091175A (en) | 1990-05-14 | 1992-02-25 | Erbamont Inc. | Pharmaceutical composition containing bile acid sequestrant enclosed in a size-exclusion membrane |
GB9011588D0 (en) | 1990-05-24 | 1990-07-11 | Wellcome Found | Prostaglandin analogues for use in medicine |
US5491397A (en) | 1992-04-30 | 1996-02-13 | Murata Kikai Kabushiki Kaisha | Motor drive device using one-two phase excitation |
US5607669A (en) | 1994-06-10 | 1997-03-04 | Geltex Pharmaceuticals, Inc. | Amine polymer sequestrant and method of cholesterol depletion |
US6129910A (en) | 1993-06-02 | 2000-10-10 | Geltex Pharmaceuticals, Inc. | Water-insoluble noncrosslinked bile acid sequestrants |
US5929184A (en) | 1993-06-02 | 1999-07-27 | Geltex Pharmaceuticals, Inc. | Hydrophilic nonamine-containing and amine-containing copolymers and their use as bile acid sequestrants |
TW474813B (en) | 1994-06-10 | 2002-02-01 | Geltex Pharma Inc | Alkylated composition for removing bile salts from a patient |
US6203785B1 (en) | 1996-12-30 | 2001-03-20 | Geltex Pharmaceuticals, Inc. | Poly(diallylamine)-based bile acid sequestrants |
US6441245B1 (en) | 1997-10-24 | 2002-08-27 | United Therapeutics Corporation | Process for stereoselective synthesis of prostacyclin derivatives |
AU1373499A (en) | 1997-11-14 | 1999-06-07 | United Therapeutics Corporation | Use of 9-deoxy-2', 9-alpha-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f1 to treat peripheral vascular disease |
US6294163B1 (en) | 1998-10-02 | 2001-09-25 | Geltex Pharmaceuticals, Inc. | Polymers containing guanidinium groups as bile acid sequestrants |
US6271264B1 (en) | 1998-12-01 | 2001-08-07 | Geltex Pharmaceuticals, Inc. | Polymers containing spirobicyclic ammonium moieties as bile acid sequestrants |
US6734215B2 (en) | 1998-12-16 | 2004-05-11 | University Of South Florida | Exo-S-mecamylamine formulation and use in treatment |
US6521212B1 (en) | 1999-03-18 | 2003-02-18 | United Therapeutics Corporation | Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation |
CA2359652A1 (en) | 1999-03-31 | 2000-10-05 | United Therapeutics Corporation | Novel prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of peripheral vascular disease and pulmonaryhypertension |
US6190649B1 (en) | 1999-04-23 | 2001-02-20 | Geltex Pharmaceuticals, Inc. | Polyether-based bile acid sequestrants |
US6700025B2 (en) | 2001-01-05 | 2004-03-02 | United Therapeutics Corporation | Process for stereoselective synthesis of prostacyclin derivatives |
ATE369851T1 (de) | 2001-01-26 | 2007-09-15 | Schering Corp | Kombinationen von gallensäuresequestriermitteln und hemmern der sterolabsorption zur behandlung von kardiovaskulären indikationen |
AU2002257145B2 (en) | 2001-04-18 | 2005-06-02 | Genzyme Corporation | Method for lowering serum glucose |
WO2003020242A1 (en) | 2001-08-29 | 2003-03-13 | Srl Technologies, Inc. | Sustained release preparations |
US6803386B2 (en) | 2002-01-16 | 2004-10-12 | United Therapeutics Corporation | Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer |
US6756117B1 (en) | 2002-12-20 | 2004-06-29 | The United States Of America As Represented By The United States Department Of Energy | Photonic polymer-blend structures and method for making |
ES2622471T5 (es) | 2003-05-22 | 2020-07-23 | United Therapeutics Corp | Compuestos y procedimientos para la administración de análogos de prostaciclina |
CA2549724C (en) | 2003-12-16 | 2014-02-11 | United Therapeutics Corporation | Use of treprostinil to treat and prevent ischemic lesions |
US20090124697A1 (en) | 2003-12-16 | 2009-05-14 | United Therapeutics Corporation | Inhalation formulations of treprostinil |
EP1696932B1 (en) | 2003-12-16 | 2009-09-02 | United Therapeutics Corporation | Use of treprostinil to improve kidney functions |
EP1699442A2 (en) | 2003-12-31 | 2006-09-13 | Genzyme Corporation | Enteric coated aliphatic amine polymer bile acid sequestrants |
DE602005020269D1 (de) | 2004-04-12 | 2010-05-12 | United Therapeutics Corp | Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren |
US20070122375A1 (en) | 2005-09-12 | 2007-05-31 | Council Of Scientific And Industrial Research | Bile acid sequestrant and process for preparation thereof |
US8747897B2 (en) | 2006-04-27 | 2014-06-10 | Supernus Pharmaceuticals, Inc. | Osmotic drug delivery system |
CN101495122B (zh) | 2006-05-15 | 2011-10-05 | 联合治疗公司 | 使用定量吸入器给予曲前列尼 |
WO2008049000A2 (en) | 2006-10-18 | 2008-04-24 | United Therapeutics Corporation | Combination therapy for pulmonary arterial hypertension |
US9205094B2 (en) | 2006-12-22 | 2015-12-08 | Ironwood Pharmaceuticals, Inc. | Compositions comprising bile acid sequestrants for treating esophageal disorders |
EP2491932A3 (en) | 2007-02-09 | 2012-12-12 | United Therapeutics Corporation | Use of biomarkers for monitoring the course of treatment of a pulmonary disease upon treatment with treprostinil |
CN103181893A (zh) | 2007-09-07 | 2013-07-03 | 联合治疗公司 | 针对革兰氏阴性细菌具有选择性杀菌活性的缓冲液及其使用方法 |
KR101898407B1 (ko) | 2007-12-17 | 2018-09-12 | 유나이티드 세러퓨틱스 코오포레이션 | 레모둘린®의 활성 성분인 트레프로스티닐의 개선된 제조 방법 |
JP5649645B2 (ja) | 2009-05-07 | 2015-01-07 | ユナイテッド セラピューティクス コーポレイション | プロスタサイクリンアナログの固形製剤 |
US20110152204A1 (en) | 2009-12-18 | 2011-06-23 | Satiogen Pharmaceuticals, Inc. | Treatment of Obesity or Diabetes with Bile Acid Sequestrants |
WO2011106545A1 (en) | 2010-02-24 | 2011-09-01 | Relypsa, Inc. | Polyimidazoles for use as bile acid sequestrants |
EP2998329A3 (en) | 2010-02-24 | 2016-04-06 | Relypsa, Inc. | Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants |
CA2791081C (en) | 2010-03-15 | 2015-08-25 | United Therapeutics Corporation | Treatment for pulmonary hypertension |
WO2011153363A1 (en) | 2010-06-03 | 2011-12-08 | United Therapeutics Corporation | Treprostinil production |
CA2710726C (en) | 2010-07-22 | 2016-02-23 | Alphora Research Inc. | Synthesis of treprostinil and intermediates useful therein |
KR101454571B1 (ko) | 2011-03-02 | 2014-10-23 | 유나이티드 세러퓨틱스 코오포레이션 | 트레프로스티닐 생산을 위한 중간체 합성 |
US9822057B2 (en) | 2013-03-14 | 2017-11-21 | United Therapeutics Corporation | Solid forms of treprostinil |
JP2016516693A (ja) | 2013-03-15 | 2016-06-09 | ユナイテッド セラピューティクス コーポレイション | トレプロスチニルの塩 |
KR102238501B1 (ko) | 2013-03-25 | 2021-04-08 | 유나이티드 세러퓨틱스 코오포레이션 | 링커 티올 및 peg화된 형태를 갖는 프로스타시클린 화합물의 제조 방법 |
-
2015
- 2015-06-12 CA CA2952223A patent/CA2952223C/en active Active
- 2015-06-12 JP JP2016572651A patent/JP2017517550A/ja active Pending
- 2015-06-12 CN CN201580043205.0A patent/CN106573066A/zh active Pending
- 2015-06-12 US US15/316,914 patent/US20170095432A1/en not_active Abandoned
- 2015-06-12 WO PCT/US2015/035595 patent/WO2015192030A1/en active Application Filing
- 2015-06-12 KR KR1020177000663A patent/KR102512890B1/ko active IP Right Grant
- 2015-06-12 EP EP15731463.4A patent/EP3164155B1/en active Active
- 2015-06-12 ES ES15731463T patent/ES2908142T3/es active Active
- 2015-06-12 AU AU2015274377A patent/AU2015274377B2/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009530298A (ja) * | 2006-03-16 | 2009-08-27 | トリス・フアルマ・インコーポレーテツド | 薬剤−イオン交換樹脂複合体を含有する放出調節製剤 |
JP2011500567A (ja) * | 2007-10-11 | 2011-01-06 | フィリップ・モーリス・プロダクツ・ソシエテ・アノニム | 生理活性物質送達のための押出可能な組成物及び押出組成物、その製造方法並びにその使用方法 |
JP2011519927A (ja) * | 2008-05-08 | 2011-07-14 | ユナイテッド セラピューティクス コーポレーション | トレプロスチニル一水和物 |
WO2009158010A1 (en) * | 2008-06-27 | 2009-12-30 | Concert Pharmaceuticals, Inc. | Prostacyclin analogs |
JP2014510128A (ja) * | 2011-04-06 | 2014-04-24 | リリアナ・ソヴィッチ・ブルキチッチ | 医薬組成物 |
WO2013024052A1 (en) * | 2011-08-12 | 2013-02-21 | Ascendis Pharma A/S | Carrier-linked treprostinil prodrugs |
WO2013024051A1 (en) * | 2011-08-12 | 2013-02-21 | Ascendis Pharma A/S | Sustained release composition of prostacyclin |
Non-Patent Citations (1)
Title |
---|
J. PHARM. SCI., vol. 101, no. 3, JPN6019005149, 2012, pages 1253 - 1266, ISSN: 0004132208 * |
Also Published As
Publication number | Publication date |
---|---|
AU2015274377A1 (en) | 2017-01-05 |
EP3164155B1 (en) | 2022-02-09 |
EP3164155A1 (en) | 2017-05-10 |
WO2015192030A1 (en) | 2015-12-17 |
CA2952223C (en) | 2023-08-01 |
KR102512890B1 (ko) | 2023-03-21 |
AU2015274377B2 (en) | 2020-07-23 |
CN106573066A (zh) | 2017-04-19 |
CA2952223A1 (en) | 2015-12-17 |
KR20170016955A (ko) | 2017-02-14 |
ES2908142T3 (es) | 2022-04-27 |
US20170095432A1 (en) | 2017-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2017517550A (ja) | トレプロスチニル製剤 | |
US20230165837A1 (en) | Novel clonidine formulation | |
KR101495146B1 (ko) | 약물 - 이온교환 수지 복합체를 함유하는 변형 방출 제제 | |
US11337920B2 (en) | Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release | |
EP2050445B1 (fr) | Composition pharmaceutique de fénofibrate présentant une biodisponibilité élevée et son procédé de préparation | |
AU2017202955B2 (en) | Extended release powder and aqueous suspension comprising methylphenidate | |
US9040083B2 (en) | Orally effective methylphenidate extended release powder and aqueous suspension product | |
EP2605757B1 (fr) | Formulations a base de nalbuphine et leurs utilisations | |
DE4200821A1 (de) | Geschmacksmaskierte pharmazeutische mittel | |
WO2015076821A1 (en) | Novel clonidine formulation | |
AU2003209673B2 (en) | Tasteless directly compressible fast-dissolving complexes and pharmaceutical formulations thereof | |
CA2731449A1 (fr) | Forme orale microparticulaire utile pour la liberation modifiee de nanoparticules | |
US11918689B1 (en) | Liquid clonidine extended release composition | |
US20230233683A1 (en) | Extended release amphetamine compositions | |
FR2676364A1 (fr) | Composition pharmaceutique a base de derives d'aminobutanone. | |
WO2023147443A2 (en) | Novel compositions | |
HUE029953T2 (en) | Oral ibuprofen lysate suspension |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180606 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190219 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190215 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190517 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20191015 |